logo

For the Inventor, By the Inventor

Stony Point, NY, United States of America

Stanley A Lang, Jr

USPTO Granted Patents = 15

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 42(Granted Patents)


Location History:

  • Stoney Point, NY (US) (1978)
  • Pomona, NY (US) (1978 - 1979)
  • Stony Point, NY (US) (1977 - 1982)
  • Blauvelt, NY (US) (1983 - 1985)

Company Filing History:

goldMedal15 out of 3,580 
 
American Cyanamid Company
 patents

Years Active: 1977-1985

Loading Chart...
15 patents (USPTO):Explore Patents
1. 4532349 - 2-Amino-4'(phenylsulfonyl) acetanilides (1985-07-30),
2. 4515954 - Metal chelates of anthracene-9,10-bis-carbonylhydrazones (1985-05-07),
3. 4419354 - 9,10-Bis(aminoalkoxy)anthracenes (1983-12-06),
4. 4329463 - Substituted 1H-1,2,4-triazoles (1982-05-11),
5. 4296030 - Metal chelates of 1,4-bis(substituted-amino-5,8-dihydroxy-anthraquinones (1981-10-20),
6. 4259504 - Substituted 1H-1,2,4-triazoles (1981-03-31),
7. 4235996 - Bis(2-imida (1980-11-25),
8. 4211726 - Synthesis of substituted 9,10-anthracene-dicarboxaldehydes and (1980-07-08),
9. 4187373 - Novel dihydrobenzanthracene derivatives (1980-02-05),
10. 4169838 - Pyrazolyltriazole herbicides (1979-10-02),
11. 4141992 - Cycloalkylcarboxyamidines and halobenzamidines as anti-amebic agents (1979-02-27),
12. 4131676 - 2,6-Bis(1-morpholinoalkylideneamino)anthraquinones as anti-amebic agents (1978-12-26),
13. 4118498 - 2,6-Bis(1-piperidinoalkylideneamino)anthraquinones and method of (1978-10-03),
14. 4115097 - Pyrazolyltriazole herbicides (1978-09-19),
15. 4029788 - 2,3-Bis(4-alkyl-1-piperazinyl)quinoxalines (1977-06-14),

Title: **The Innovative Mind of Stanley A. Lang, Jr.**

Introduction

Stanley A. Lang, Jr., an accomplished inventor based in Stony Point, NY, has made significant contributions to the field of pharmaceuticals and medical chemistry. With a remarkable portfolio of 15 patents, Lang has developed a deep understanding of immune modulation and antibacterial agents, showcasing his commitment to advancing healthcare solutions.

Latest Patents

Lang's latest innovations include two noteworthy patents. The first patent revolves around 2-Amino-4'(phenylsulfonyl) acetanilides, which describes a method of modulating the immune response system in warm-blooded animals through the administration of N-substituted-phenylthioanilines, N-substituted-phenylsulfinylanilines, and N-substituted-phenylsulfonylanilines. This invention introduces several new compounds that hold promise for therapeutic applications. His second latest patent concerns metal chelates of anthracene-9,10-bis-carbonylhydrazones. This invention is significant due to its potential use as antibacterial agents and its ability to inhibit the growth of transplanted mouse tumors, as well as its role in inducing regression and palliation of leukemia and related cancers.

Career Highlights

Stanley A. Lang, Jr. is affiliated with the American Cyanamid Company, where he has been able to channel his innovation into practical applications. Over the years, his work has strengthened the company’s position in the pharmaceutical sector, influencing advancements in medicinal chemistry and therapeutic practices.

Collaborations

Throughout his career, Lang has collaborated with notable colleagues, including Yang-I Lin and Keith C. Murdock. These partnerships have contributed to the depth and breadth of his research and development efforts, fostering an environment of innovation and shared expertise.

Conclusion

In summary, Stanley A. Lang, Jr. exemplifies the spirit of innovation in the realm of medical chemistry. With a strong patent portfolio and impactful collaborations, Lang continues to pave the way for advancements that could significantly enhance healthcare outcomes for various diseases. His work not only showcases his ingenuity but also his dedication to the improvement of medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…